Promoting Me-Too Biologicals: Portfolio vs. Single Product Approach
Executive Summary
Novo Nordisk's grand plan for pitting its new basal insulin Levemir against Aventis' dominant Lantus is to promote the product in the context of the company's broader insulin portfolio. Novo believes its portfolio approach should capture a greater overall share of the insulin space than Aventis with its one-size-fits-all strategy.
You may also be interested in...
Antegren: Shaking Up the MS Market?
The dynamics of specialty chronic care markets suggest that Biogen Idec and Elan's highly anticipated Antegren may have trouble turning the scrappy $3.5 billion MS market on its head, at least right away.
Antegren: Shaking Up the MS Market?
The dynamics of specialty chronic care markets suggest that Biogen Idec and Elan's highly anticipated Antegren may have trouble turning the scrappy $3.5 billion MS market on its head, at least right away.
Aventis: Building on a Base in Diabetes
Aventis is looking to the diabetes market to boost future growth. Lantus, the company's novel once-a-day injectable insulin, will spearhead the move. But can Aventis use an injectable to break into the fast growing Type II segment?